Clinical Education InitiativeMenu
Search
Home > Courses > Update on Vaginal and Rectal Microbicides for HIV Prevention

Update on Vaginal and Rectal Microbicides for HIV Prevention

Update on Vaginal and Rectal Microbicides for HIV Prevention
Update on Vaginal and Rectal Microbicides for HIV Prevention
Play
Sorry, this learning module is not available for mobile devices.
Resource ID: CM371
Original Presentation: 2/10/2015
Web Posting: 5/4/2015
CE Expiration: 02/10/2018
Presenter
  • Ian M. McGowan, MD, PhD, FRCP
    Professor of Medicine
    Division of Gastroenterology, Hepatology & Nutrition, University of Pittsburgh, Pittsburgh, PA
Learning Objectives
At the completion of this educational session, participants will:
  1. Appreciate the process of microbicide development.
  2. Be aware of the current status of lead vaginal and rectal microbicide candidates.
  3. Understand the critical path towards product availability for HIV prevention.
Presenter Bio
Ian M. McGowan, MD, PhD, FRCP
Ian McGowan is a Professor of Medicine at the University of Pittsburgh School of Medicine. Originally trained in medicine at the University of Liverpool, UK, he also has doctoral degrees from Oxford University, UK in mucosal immunology and the Liverpool University, UK in tropical medicine. Since 1989, he has been involved in clinical and research programs related to sexual health, the diagnosis and management of sexually transmitted infections (including HIV infection), translational research related to the mucosal pathogenesis of HIV infection, and the development of antiretroviral therapy to treat and prevent HIV infection. He is currently the Principal Investigator of the University of Pittsburgh-based Microbicide Trials Network (MTN), an HIV/AIDS clinical trials network established in 2006, and renewed in 2013, by the National Institute of Allergy and Infectious Diseases to develop topical microbicides for HIV prevention. This position includes providing oversight for the conduct of Phase 1 through Phase 3 clinical trials of novel microbicides in the US, Sub-Saharan Africa, Thailand, and Peru.
Continuing Education Credit

This CME activity was approved for AMA PRA Category 1 Credit™ on February 10, 2015 and will terminate February, 2018.

The target audience is all physicians, NPs and PAs involved or interested in HIV education.

This online video and post-activity evaluation are one hour in length. 

  • After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz. 
  • You must achieve at least 70% correct to receive your CME certificate. 
  • If successful, you will be provided instructions to print your CME certificate at the completion of this activity. 

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with extent of their participation in the activity.

Disclosure Statement 

Policies and standards of MSSNY require that speakers and planners for CME activities disclose any relevant financial relationships they may have with commercial interests whose products, devices or services may be discussed in the content of a CME activity.  

  • Dr. James Braun (Planner/Course Director) had no relevant financial relationships to disclose. 
  • Dr. McGowan (Presenter) had no relevant financial relationships to disclose. Dr. McGowan supported his presentation and clinical recommendations with the best available evidence from the medical literature, and submitted his slides in advance for adequate peer review.

Financial Support

This meeting of the Physicians’ Research Network (PRN) and enduring material were funded in part by educational grants from: Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Merck & Co, and ViiV Healthcare.

PRN Learning Modules